Strides Arcolab’s arm receives USFDA approval for Cisplatin Injection

19 Apr 2012 Evaluate

Strides Arcolab’s wholly owned subsidiary - Onco Therapies, has received USFDA approvals for Cisplatin Injection, 1 mg/mL packages in 50 mL and 100 mL multiple dose vials. Cisplatin is amongst the products in the drug shortage list of USFDA. According to IMS data, the US market for generic Cisplatin is approximately $10 million.

Cisplatin is part of the oncology portfolio licensed to Pfizer in January 2010 for the US market and expected to be launched shortly. Cisplatin is a chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas, and germ cell tumors.

Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterile injectables. 

Strides Pharma Scien Share Price

943.35 -5.80 (-0.61%)
01-Jul-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1517.90
Dr. Reddys Lab 6362.00
Cipla 1478.90
Zydus Lifesciences 1066.95
Lupin 1614.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.